163213-29-4 Usage
Uses
Used in Medicinal Chemistry:
DIMETHYL 1-(2-BROMOETHYL)-1H-PYRAZOLE-3,5-DICARBOXYLATE is used as a key intermediate in the synthesis of pharmaceuticals for its potential to contribute to the development of new drugs with enhanced biological activity.
Used in Agrochemical Synthesis:
In the agrochemical industry, DIMETHYL 1-(2-BROMOETHYL)-1H-PYRAZOLE-3,5-DICARBOXYLATE is used as a precursor in the creation of agrochemicals, leveraging its chemical properties to improve the effectiveness of these products.
Used in Organic Chemistry Research:
DIMETHYL 1-(2-BROMOETHYL)-1H-PYRAZOLE-3,5-DICARBOXYLATE is utilized as a research compound in organic chemistry, providing a foundation for exploring new reactions and mechanisms that could lead to innovative synthetic pathways and the discovery of novel compounds.
Used in Drug Discovery and Design:
The unique chemical structure of DIMETHYL 1-(2-BROMOETHYL)-1H-PYRAZOLE-3,5-DICARBOXYLATE makes it a versatile tool in drug discovery and design, where it can be employed to construct new molecular entities with potential therapeutic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 163213-29-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,3,2,1 and 3 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 163213-29:
(8*1)+(7*6)+(6*3)+(5*2)+(4*1)+(3*3)+(2*2)+(1*9)=104
104 % 10 = 4
So 163213-29-4 is a valid CAS Registry Number.
InChI:InChI=1/C9H11BrN2O4/c1-15-8(13)6-5-7(9(14)16-2)12(11-6)4-3-10/h5H,3-4H2,1-2H3
163213-29-4Relevant academic research and scientific papers
Fibrinogen receptor antagonists
-
, (2008/06/13)
Compounds of the invention have the formula STR1 The compounds have fibrinogen receptor antagonist activity.
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists
Askew, Benny C.,Bednar, Rodney A.,Bednar, Bohumil,Claremon, David A.,Cook, Jacquelynn J.,McIntyre, Charles J.,Hunt, Cecila A.,Gould, Robert J.,Lynch, Robert J.,Lynch Jr., Joseph J.,Gaul, Stanley L.,Stranieri, Maria T.,Sitko, Gary R.,Holahan, Marie A.,Glass, Joan D.,Hamill, Terrence,Gorham, Lynn M.,Prueksaritanont, Thomayant,Baldwin, John J.,Hartman, George D.
, p. 1779 - 1788 (2007/10/03)
The synthesis and pharmacological evaluation of 5 (L-738,167), a potent, selective non-peptide fibrinogen receptor antagonist is reported. Compound 5 inhibited the aggregation of human gel-filtered platelets with an IC50 value of 8 nM and was found to be >33000-fold less effective at inhibiting the attachment of human endothelial cells to fibrinogen, fibronectin, and vitronectin than it was at inhibiting platelet aggregation. Ex vivo platelet aggregation was inhibited by >85% 24 h after the oral administration of 5 to dogs at 100 μg/kg. The extended pharmacodynamic profile exhibited by 5 appears to be a consequence of its high-affinity binding to GPIIb/IIIa on circulating platelets and suggests that 5 is suitable for once-a-day dosing.
